二线纳武单抗/贝伐单抗治疗复发性肝细胞癌肝移植患者的可行性、安全性及疗效 - Suppr

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma.

作者信息

Di Marco Lorenza, Pivetti Alessandra, Foschi Francesco Giuseppe, D'Amico Roberto, Schepis Filippo, Caporali Cristian, Casari Federico, Lasagni Simone, Critelli Rosina Maria, Milosa Fabiola, Romanzi Adriana, Marcelli Gemma, De Maria Nicola, Romagnoli Dante, Catellani Barbara, Scianò Filippo, Magistri Paolo, Colecchia Antonio, Sighinolfi Pamela, Di Benedetto Fabrizio, Martinez-Chantar Maria-Luz, Villa Erica

机构信息

Department of Medical Specialties, Gastroenterology Unit, University of Modena & Reggio Emilia and Azienda Ospedaliero-Universitaria di Modena, Via del Pozzo 71, Modena, Italy.

Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.

出版信息

Liver Transpl. 2023 May 1;29(5):559-563. doi: 10.1097/LVT.0000000000000087. Epub 2023 Feb 8.

DOI:10.1097/LVT.0000000000000087

PMID:36747351

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10106106/

Abstract

摘要

相似文献

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma.二线纳武单抗/贝伐单抗治疗复发性肝细胞癌肝移植患者的可行性、安全性及疗效

Liver Transpl. 2023 May 1;29(5):559-563. doi: 10.1097/LVT.0000000000000087. Epub 2023 Feb 8.

Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation.阿替利珠单抗联合贝伐单抗作为肝移植后复发性肝细胞癌挽救治疗的初步评估

Liver Transpl. 2022 May;28(5):895-896. doi: 10.1002/lt.26416. Epub 2022 Feb 24.

Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.肝移植术后因移植前纳武利尤单抗治疗引发的严重排斥反应导致移植物丢失后的挽救性肝再移植。

Clin J Gastroenterol. 2021 Dec;14(6):1718-1724. doi: 10.1007/s12328-021-01521-4. Epub 2021 Oct 13.

A Psoriasiform Drug Eruption Secondary to Nivolumab for Hepatocellular Carcinoma: A Case Report.一例因纳武单抗治疗肝细胞癌继发的银屑病样药疹：病例报告

Hepatology. 2019 Oct;70(4):1477-1479. doi: 10.1002/hep.30659. Epub 2019 May 20.

Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients.奥沙利铂、5-氟尿嘧啶和亚叶酸（FOLFOX-4）在肝硬化或肝移植患者中的可行性：晚期肝细胞癌患者队列中的经验。

Invest New Drugs. 2012 Feb;30(1):376-81. doi: 10.1007/s10637-010-9525-0. Epub 2010 Aug 27.

Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.索拉非尼作为肝移植受者高危肝细胞癌辅助治疗的可行性和疗效

Exp Clin Transplant. 2010 Dec;8(4):307-13.

Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab.纳武利尤单抗治疗后行肝移植治疗肝细胞癌。

Am J Transplant. 2022 Jun;22(6):1699-1704. doi: 10.1111/ajt.16965. Epub 2022 Feb 8.

Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.优化免疫检查点抑制剂（阿替利珠单抗、纳武利尤单抗或帕博利珠单抗）治疗后肝移植的安全洗脱期。

Transplant Proc. 2023 May;55(4):878-883. doi: 10.1016/j.transproceed.2023.03.064. Epub 2023 Apr 29.

Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?尼伏单抗桥接肝移植治疗 HCC 后致死性肝坏死：免疫检查点抑制剂对移植前患者安全吗？

Am J Transplant. 2020 Mar;20(3):879-883. doi: 10.1111/ajt.15617. Epub 2019 Oct 28.

Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.纳武利尤单抗治疗后肝细胞癌肝切除标本中肿瘤和非肿瘤组织的形态学。

Mod Pathol. 2021 Apr;34(4):823-833. doi: 10.1038/s41379-020-00679-5. Epub 2020 Sep 28.

引用本文的文献

Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma.肝细胞癌的肿瘤微环境与免疫治疗策略进展

Oncol Res. 2025 Aug 28;33(9):2309-2329. doi: 10.32604/or.2025.063719. eCollection 2025.

Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors.肝移植后肝细胞癌复发的管理：免疫检查点抑制剂的新作用

Discov Oncol. 2025 Jul 28;16(1):1431. doi: 10.1007/s12672-025-03226-3.

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis.接受免疫检查点抑制剂治疗的晚期癌症实体器官移植受者的结局：一项系统评价和个体参与者数据荟萃分析。

JAMA Oncol. 2025 Jun 22. doi: 10.1001/jamaoncol.2025.2374.

Sorafenib as Adjuvant Therapy Post-Liver Transplant: A Single-center Experience.索拉非尼作为肝移植术后辅助治疗：单中心经验

Transplant Direct. 2025 Jan 23;11(2):e1746. doi: 10.1097/TXD.0000000000001746. eCollection 2025 Feb.

Liver resection and transplantation in the era of checkpoint inhibitors.免疫检查点抑制剂时代的肝切除与肝移植

JHEP Rep. 2024 Aug 6;6(11):101181. doi: 10.1016/j.jhepr.2024.101181. eCollection 2024 Nov.

APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.2024年亚太肝脏研究学会肝细胞癌全身治疗临床实践指南

Hepatol Int. 2024 Dec;18(6):1661-1683. doi: 10.1007/s12072-024-10732-z. Epub 2024 Nov 21.

The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment.新生血管生成转录组特征影响肝细胞癌预后，且可由经动脉化疗栓塞治疗触发。

Cancers (Basel). 2024 Oct 21;16(20):3549. doi: 10.3390/cancers16203549.

Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors.免疫检查点抑制剂时代肝细胞癌的肝移植

Cancers (Basel). 2024 Jun 28;16(13):2374. doi: 10.3390/cancers16132374.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献